Evidence map›Paper›PMID 33413990›Full record

ArticleEnfermedades infecciosas y microbiologia clinica (English ed.)2020

Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain.

Teresa Nebreda-Mayoral, María Antonia Miguel-Gómez, Gabriel Alberto March-Rosselló, Lucía Puente-Fuertes, Elena Cantón-Benito, Ana María Martínez-García, Ana Belén Muñoz-Martín, Antonio Orduña-Domingo

Open access · greenAbstract read
In one paragraph

Article in Enfermedades infecciosas y microbiologia clinica (English ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. The Impact of Multidrug-ResistantHealthcare (Basel, Switzerland) · 2023
    Article
  6. [Etiology of bacterial pneumonias in patients with COVID-19].Revista medica del Instituto Mexicano del Seguro Social · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Cefiderocol for Severe Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Pathogens (Basel, Switzerland) · 2021
    Review
  16. Pathogens (Basel, Switzerland) · 2021
    Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Teresa Nebreda-MayoralServicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, España. Electronic address: tnebreda@saludcastillayleon.es.
María Antonia Miguel-GómezServicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Gabriel Alberto March-RossellóServicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Lucía Puente-FuertesServicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Elena Cantón-BenitoServicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Ana María Martínez-GarcíaServicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Ana Belén Muñoz-MartínServicio de Farmacia, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Antonio Orduña-DomingoServicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, España.
Hospital Clínico Universitario de Valladolid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBacterial/fungal coinfection and superinfections contribute to the increased morbi-mortality of viral respiratory infections (RIs). The main objective of this study was to determine the incidence of these infections in hospitalized patients with COVID-19.

methodRetrospective observational study of all patients admitted for COVID-19 and bacterial/fungal infections at the Hospital Clínico Universitario of Valladolid, Spain (March 1-May 31, 2020). Demographic, clinical and microbiological data were compared based on Intensive Care Unit (ICU) admission and predictors of mortality by were identified using multivariate logistic regression analyses.

resultsOf the 712 COVID-19 patients, 113 (16%) presented bacterial/fungal coinfections or superinfections. Their median age was 73 years (IQR 57-89) and 59% were men. The profiles of ICU patients (44%) included male, SARS-CoV-2 pneumonia, leukocytosis, elevated inteleukin-6, with interferon β-1b and tocilizumab and superinfection (p < 0.05). Coinfections were diagnosed in 5% (39/712) patients. Most common pathogens of respiratory coinfection (18) were Streptococcus pneumoniae (6) and Staphylococcus aureus (6). Superinfections were detected in 11% (80/712) patients. Urinary (53) and RIs (39) constituted the majority of superinfections Acinetobacter baumannii multidrug-resistant was the main agent of IR and bacteremia. An outbreak of A. baumannii contributed to this result. Three patients were considered to have probable pulmonary aspergillosis. Mortality was higher in UCI patients (50 vs. 29%; p = 0.028). The predictive factors of mortality included being a male with various comorbidities, SARS-CoV-2 pneumonia, bacteremia and superinfections from A. baumannii.

conclusionThe outbreak of A. baumannii was a determining factor in the increases of the incidence of infection and the morbi-mortality of ICU patients.

Indexed as

Acinetobacter baumanniiBroteCoinfecciónCoinfectionCOVID-19OutbreakSARS-CoV-2SobreinfecciónSuperinfections

Identifiers

PMID33413990
PMCPMC7713607
OpenAlexW3120133411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.